NFKBIE Antibody

What is NFKBIE and why is it significant in research?

NFKBIE (Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, epsilon) is a critical inhibitor of the NF-κB signaling pathway that regulates immune response, inflammation, and cell survival. This protein functions by sequestering NF-κB transcription factors in the cytoplasm, preventing their nuclear translocation and subsequent activation of target genes . NFKBIE is particularly significant in research because dysregulation of the NF-κB pathway is implicated in numerous pathological conditions including cancer, autoimmune diseases, and inflammatory disorders. The study of NFKBIE has revealed its role as a prognostic factor in hepatocellular carcinoma and its involvement in immune cell infiltration, making it an important target for immunotherapy research .

How does NFKBIE function in the NF-κB signaling pathway?

NFKBIE encodes IκBε, which belongs to the family of NF-κB inhibitors that regulate the activity of NF-κB transcription factors. In the canonical NF-κB pathway, IκBε binds to NF-κB dimers (primarily composed of subunits such as p65, RelB, c-Rel, p50, and p52), preventing their nuclear translocation . Upon cellular stimulation through various receptors (e.g., B-cell receptor, toll-like receptors), IκBε undergoes phosphorylation, ubiquitination, and subsequent proteasomal degradation, allowing NF-κB to enter the nucleus and activate transcription of target genes . This pathway is crucial for immune cell function, inflammation resolution, and cell survival decisions. Loss-of-function mutations in NFKBIE, as observed in certain B-cell malignancies, lead to enhanced NF-κB activity and can contribute to disease progression through increased cell proliferation, altered immune microenvironment, and therapy resistance .

What are the primary experimental applications for NFKBIE antibodies?

NFKBIE antibodies are versatile tools in molecular and cellular research with applications in:

• Western Blotting (WB): Allows quantification of NFKBIE protein expression levels and detection of post-translational modifications, particularly useful in comparing expression between normal and disease tissues .

• Immunohistochemistry (IHC): Enables visualization of NFKBIE expression patterns in tissue sections, critical for analyzing spatial distribution in tumor microenvironments and assessing correlation with clinical parameters .

• Immunocytochemistry (ICC): Permits subcellular localization studies of NFKBIE in cultured cells under various stimulation conditions .

• Immunofluorescence (IF): Facilitates co-localization studies with other proteins in the NF-κB pathway, allowing researchers to investigate protein-protein interactions and pathway dynamics .

• Chromatin Immunoprecipitation (ChIP): While less common for NFKBIE directly, antibodies against NF-κB components can be used to study how NFKBIE alterations affect DNA binding of transcription factors.

Selection of the appropriate application depends on the specific research question, with consideration for antibody specificity, sample preparation requirements, and detection sensitivity needs .

How should researchers validate NFKBIE antibody specificity for experimental use?

Validating NFKBIE antibody specificity is essential for ensuring reliable experimental results. A comprehensive validation protocol includes:

• Positive and negative controls: Use cell lines or tissues with known NFKBIE expression levels. For negative controls, consider NFKBIE-knockout cells created through CRISPR-Cas9 or cells with siRNA-mediated knockdown of NFKBIE, as demonstrated in hepatocellular carcinoma research .

• Multiple antibody comparison: Compare results using different antibodies targeting distinct epitopes of NFKBIE. For instance, antibodies targeting different regions (e.g., AA 115-350, AA 131-180, AA 140-280) should show consistent patterns .

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide before application to samples. Specific signals should be significantly reduced or eliminated.

• Western blot analysis: Confirm antibody detects a protein of the correct molecular weight (~45 kDa for NFKBIE) and shows differential expression in appropriate contexts (e.g., higher expression in B cells compared to T cells) .

• Phospho-specific validation: For phospho-specific antibodies (e.g., pSer157, pSer161), validate using phosphatase treatment controls and stimulation conditions known to induce phosphorylation.

Researchers should also verify reactivity with the specific species under investigation, as antibody performance can vary significantly across species despite sequence homology .

How can researchers effectively study NFKBIE mutations and their functional consequences?

Studying NFKBIE mutations requires a multifaceted approach combining genomic, transcriptomic, and functional analyses:

• Mutation identification strategies:

  • Targeted sequencing of NFKBIE exons, particularly focusing on hotspot regions like the insertion-deletion variant rs28362491 .

  • Whole exome sequencing for comprehensive mutation profiling, particularly useful in cancer studies where multiple genetic alterations may coexist .

  • Digital droplet PCR for sensitive detection of low-frequency mutations, especially in heterogeneous samples .

• Functional validation approaches:

  • Luciferase reporter assays using NF-κB response elements to measure pathway activation, as demonstrated in studies showing NFKBIE variant effects on transcriptional activity .

  • CRISPR-Cas9 gene editing to introduce specific mutations or create isogenic cell line pairs.

  • Site-directed mutagenesis to generate expression constructs with specific NFKBIE variants for overexpression studies.

• Transcriptional impact assessment:

  • RNA-sequencing to identify differentially expressed genes following NFKBIE mutation or knockdown, as seen in HCC studies where NFKBIE affected antigen processing and presentation pathways .

  • Allele-specific transcript quantification (ASTQ) to measure differential expression between wild-type and mutant alleles, revealing cis-regulatory effects of mutations .

  • ChIP-seq to map genome-wide binding patterns of NF-κB components when NFKBIE function is altered.

• Protein interaction studies:

  • Co-immunoprecipitation to assess how mutations affect interactions with NF-κB subunits like RELA, REL, and RELB .

  • Proximity ligation assays to visualize protein-protein interactions in situ.

This comprehensive approach enables researchers to connect genetic alterations in NFKBIE with their molecular, cellular, and potentially clinical consequences .

What are the methodological considerations when studying NFKBIE in different immune cell populations?

Studying NFKBIE across immune cell populations requires consideration of cell-specific expression patterns, activation states, and methodological adaptations:

• Cell isolation and purity considerations:

  • Use fluorescence-activated cell sorting (FACS) or magnetic separation for high-purity isolation of specific immune subsets (B cells, T cells, macrophages).

  • Consider density gradient separation methods for peripheral blood mononuclear cells (PBMCs) before subset isolation.

  • Verify population purity using flow cytometry with lineage-specific markers (>95% purity recommended).

• Cell-specific expression analysis:

  • Account for differential baseline expression of NFKBIE across immune cells (e.g., higher in memory B cells compared to T cells as shown in HCC studies) .

  • Compare expression levels in resting versus activated states, as NF-κB pathway components are highly regulated during immune activation.

  • Consider single-cell RNA sequencing to capture heterogeneity within populations, particularly important in tumor microenvironments.

• Activation conditions optimization:

  • For B cells: Anti-IgM, CD40L, or CpG stimulation activates different branches of the NF-κB pathway.

  • For T cells: Anti-CD3/CD28 stimulation, PMA/ionomycin, or cytokine treatments.

  • For myeloid cells: LPS, cytokines (e.g., TNF-α, IL-1β), or pathogen-associated molecular patterns.

  • Include time-course experiments (15 min to 48 hours) to capture dynamic regulation of NFKBIE.

• Context-specific protein complexes:

  • Analyze NFKBIE interactions with different NF-κB subunits that may predominate in specific cell types (e.g., c-Rel in B cells).

  • Consider crosslinking approaches for transient interactions.

• Tissue-specific considerations:

  • For tissue-resident immune cells, optimize extraction protocols to maintain cellular integrity.

  • Consider laser capture microdissection for studying immune cells in their tissue context.

These methodological considerations ensure accurate characterization of NFKBIE function in the context of immune cell diversity and activation states .

How does NFKBIE expression correlate with clinical outcomes in cancer research?

NFKBIE expression and mutation status have significant correlations with clinical outcomes across multiple cancer types, with noteworthy differences in prognostic implications:

• Hepatocellular Carcinoma (HCC):

  • NFKBIE is overexpressed in HCC compared to normal liver tissues, distinguishing it from other NF-κB inhibitors .

  • Higher NFKBIE expression correlates with improved prognosis in HCC, making it a potential positive prognostic biomarker .

  • NFKBIE expression is associated with tumor grade, stage, and TP53 mutation status, reflecting its biological relevance to disease progression .

  • Mechanistically, NFKBIE may inhibit multiple oncogenic pathways in HCC, including PI3K/AKT, RAS/MAPK, RTK, and TSC/mTOR signaling .

• Chronic Lymphocytic Leukemia (CLL):

  • In contrast to HCC, loss-of-function mutations in NFKBIE are frequent in CLL and associate with accelerated disease progression .

  • NFKBIE mutations correlate with inferior responses to chemotherapy and BTK inhibitor treatment (e.g., ibrutinib) .

  • NFKBIE-mutated CLL shows altered tumor microenvironment with increased T-cell exhaustion markers and PD-L1 expression, suggesting immune escape mechanisms .

  • Almost all cases with NFKBIE aberrations occur in unmutated IGHV CLL (U-CLL), a subgroup with generally poorer prognosis .

• Other B-cell malignancies:

  • Low-frequency (<10%) 4-bp NFKBIE deletions are observed in aggressive lymphoma variants .

  • Functional loss of NFKBIE leads to NF-κB deregulation that may drive disease aggression .

These contrasting roles highlight the context-dependent function of NFKBIE, necessitating cancer-specific interpretation of its expression or mutation status when evaluating potential as a biomarker or therapeutic target .

What methods should be used to investigate NFKBIE's role in immune infiltration and the tumor microenvironment?

Investigating NFKBIE's role in immune infiltration and the tumor microenvironment requires integrated methodological approaches:

• Computational immune deconvolution methods:

  • Utilize databases like TIMER (Tumor Immune Estimation Resource) to analyze correlations between NFKBIE expression and immune cell infiltration across cancer types .

  • Apply algorithms such as CIBERSORT, xCell, or MCP-counter to RNA-seq data for estimating immune cell type proportions.

  • Integrate with clinical data to assess prognostic implications of combined NFKBIE status and immune infiltration patterns .

• Spatial characterization approaches:

  • Multiplex immunohistochemistry or immunofluorescence to visualize NFKBIE expression alongside immune cell markers in tissue sections.

  • Spatial transcriptomics to map gene expression changes in tumor and immune compartments with spatial resolution.

  • Digital pathology quantification using software solutions that enable objective scoring of immune cell density and distribution.

• Functional interaction studies:

  • Co-culture experiments with NFKBIE-modified tumor cells and immune cells to assess direct effects on immune function and activation.

  • Conditioned media experiments to identify secreted factors affected by NFKBIE status.

  • Immune cell functional assays (cytotoxicity, cytokine production, proliferation) following exposure to NFKBIE-manipulated tumor cells.

• In vivo modeling:

  • Syngeneic mouse models with NFKBIE-modified tumor cells to study immune infiltration in an immunocompetent context.

  • Flow cytometry of tumor-infiltrating lymphocytes to phenotype immune populations, including exhaustion markers (PD-1, CTLA-4, LAG-3, TIM-3) .

  • Single-cell RNA-seq of tumor and immune cells to capture heterogeneity and identify cell-specific effects of NFKBIE alterations.

• Cytokine/chemokine profiling:

  • Multiplex cytokine arrays to measure inflammatory mediators affected by NFKBIE status.

  • ELISA or cytometric bead array of culture supernatants or plasma samples.

These approaches collectively enable researchers to decipher the complex interplay between NFKBIE, cancer cells, and the immune microenvironment, potentially identifying new immunotherapeutic strategies .

What are the common pitfalls in NFKBIE detection and quantification, and how can they be addressed?

Researchers encounter several technical challenges when working with NFKBIE antibodies that require specific troubleshooting strategies:

• Cross-reactivity with other IκB family members:

  • Challenge: NFKBIE (IκBε) shares sequence homology with other IκB family proteins (IκBα, IκBβ).

  • Solution: Select antibodies targeting unique regions of NFKBIE (e.g., AA 115-350) . Validate specificity using knockout controls or competition assays with specific peptides. Consider Western blot confirmation before immunostaining applications.

• Low sensitivity in detection of endogenous levels:

  • Challenge: Endogenous NFKBIE may be expressed at levels below detection limits of some antibodies.

  • Solution: Implement signal amplification methods such as tyramide signal amplification for IHC/ICC applications. For Western blotting, use high-sensitivity ECL substrates and optimize protein loading (50-100 μg of total protein recommended). Consider concentrating protein using immunoprecipitation before detection.

• Dynamic regulation and rapid degradation:

  • Challenge: NFKBIE undergoes rapid degradation following pathway stimulation, complicating time-point selection.

  • Solution: Perform careful time-course experiments following stimulation. Use proteasome inhibitors (e.g., MG132) to prevent degradation when analyzing total protein levels. For phosphorylated forms, include phosphatase inhibitors in lysis buffers.

• Fixation artifacts in tissue samples:

  • Challenge: Overfixation can mask epitopes and reduce antibody binding.

  • Solution: Optimize fixation protocols (4% paraformaldehyde for 24-48 hours is often suitable). Implement antigen retrieval methods, particularly Tris-EDTA based protocols as used in HCC tissue microarray studies . Test multiple antibodies targeting different epitopes.

• Quantification inconsistencies:

  • Challenge: Variability in staining intensity and distribution complicates quantification.

  • Solution: Use digital image analysis with standardized scoring systems. Include reference standards on each blot/slide. Consider multiplexed approaches that include housekeeping proteins or structural markers for normalization.

• Isoform-specific detection:

  • Challenge: NFKBIE may exist in multiple isoforms or post-translationally modified states.

  • Solution: Use antibodies that specifically recognize relevant modifications (e.g., phospho-specific antibodies targeting pSer157, pSer161, or pSer22) . Confirm isoform specificity using recombinant protein controls.

Addressing these technical considerations ensures more reliable and reproducible results when studying NFKBIE in research contexts .

How can researchers optimize protocols for detecting NFKBIE phosphorylation and post-translational modifications?

Detecting phosphorylation and other post-translational modifications (PTMs) of NFKBIE requires specialized approaches:

• Phosphorylation-specific detection optimization:

  • Immediately lyse cells in buffers containing phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) to preserve phosphorylation states.

  • For Western blotting, use phospho-specific antibodies targeting known regulatory sites (pSer157, pSer161, pSer22) and confirm specificity with lambda phosphatase treatment controls.

  • Optimize stimulation conditions that induce phosphorylation, such as PMA/ionomycin for 15-30 minutes for immune cells or TNF-α treatment (10-20 ng/ml) for epithelial cells.

  • Consider Phos-tag SDS-PAGE for enhanced separation of phosphorylated protein species without requiring phospho-specific antibodies.

• Ubiquitination detection strategies:

  • Include deubiquitinase inhibitors (N-ethylmaleimide) in lysis buffers.

  • Perform denaturing immunoprecipitation to disrupt protein complexes and reveal ubiquitination sites.

  • Use tagged ubiquitin constructs (HA-Ub, FLAG-Ub) in overexpression systems for enhanced detection sensitivity.

  • Consider specific antibodies against ubiquitin linkage types (K48, K63) to distinguish between degradative and non-degradative ubiquitination.

• Advanced mass spectrometry approaches:

  • Implement enrichment strategies for phosphopeptides using titanium dioxide (TiO2) or immobilized metal affinity chromatography (IMAC).

  • Use parallel reaction monitoring (PRM) for targeted quantification of specific modified peptides.

  • Consider stable isotope labeling with amino acids in cell culture (SILAC) for comparative quantification of PTMs across experimental conditions.

  • Employ data-independent acquisition (DIA) mass spectrometry for comprehensive PTM profiling.

• Temporal dynamics analysis:

  • Design detailed time-course experiments spanning seconds to hours post-stimulation.

  • Use synchronized cell populations to minimize variation in signaling responses.

  • Consider live-cell imaging with fluorescent reporters for real-time monitoring of pathway activation.

• Sub-cellular localization assessment:

  • Perform careful subcellular fractionation to track NFKBIE movement between cytoplasmic and nuclear compartments.

  • Use immunofluorescence with confocal microscopy to visualize localization changes in response to stimuli.

  • Combine with proximity ligation assays to detect interactions with relevant binding partners in different cellular compartments.

These optimized approaches enable researchers to precisely track the dynamic post-translational regulation of NFKBIE, which is critical for understanding its function in normal physiology and disease contexts .

How can researchers translate NFKBIE findings into potential therapeutic strategies?

Translating NFKBIE research findings into therapeutic strategies requires systematic approaches that bridge basic science and clinical application:

• Target validation strategies:

  • Confirm disease relevance through correlation of NFKBIE alterations with patient outcomes across multiple independent cohorts .

  • Validate functional significance using gene editing in relevant cell lines and patient-derived models.

  • Identify synthetic lethal interactions with NFKBIE mutations that could reveal druggable dependencies.

  • Determine tissue-specific effects to anticipate potential on-target toxicities.

• Therapeutic approaches for NFKBIE-deficient cancers:

  • For cancers with NFKBIE loss-of-function (e.g., CLL), consider downstream NF-κB pathway inhibitors:

    • IKK inhibitors that prevent activation of the remaining IκB proteins

    • Proteasome inhibitors that block degradation of IκB proteins

    • Direct NF-κB inhibitors that prevent DNA binding or transcriptional activity

  • Target synthetic lethal partners identified through functional genomic screens.

  • Develop immunotherapeutic approaches based on altered immune microenvironment (e.g., PD-1/PD-L1 blockade for NFKBIE-mutated CLL with increased PD-L1 expression) .

• Approaches for NFKBIE-overexpressing cancers:

  • For cancers where NFKBIE is overexpressed (e.g., HCC), consider:

    • Targeting components of "antigen processing and presentation" pathways that are affected by NFKBIE .

    • Developing combination approaches with existing therapies based on pathway interactions (e.g., PI3K/AKT inhibitors) .

    • Using NFKBIE as a stratification biomarker for patient selection in clinical trials.

• Drug resistance considerations:

  • Address potential resistance mechanisms, as NFKBIE mutations are associated with reduced sensitivity to ibrutinib in CLL .

  • Develop combination strategies to overcome resistance (e.g., combining BTK inhibitors with other targeted agents).

  • Implement longitudinal monitoring for emergence of NFKBIE alterations during treatment.

• Biomarker development pipeline:

  • Standardize detection methods for NFKBIE mutations or expression.

  • Validate prognostic significance in prospective clinical studies.

  • Develop companion diagnostics if NFKBIE status predicts response to specific therapies.

This translational framework enables researchers to leverage NFKBIE biology for developing novel therapeutic strategies while addressing potential challenges in clinical implementation .

What are the methodological approaches to study NFKBIE's role in drug resistance mechanisms?

Understanding NFKBIE's contribution to drug resistance requires specialized methodological approaches:

• Clinical correlation studies:

  • Analyze NFKBIE mutation/expression status in paired pre-treatment and relapse samples from patients.

  • Perform retrospective analyses of clinical trial cohorts to correlate NFKBIE status with treatment outcomes, as demonstrated in CLL patients treated with ibrutinib .

  • Implement multivariate analyses to determine if NFKBIE alterations are independent predictors of response.

  • Consider time-to-event analyses (progression-free survival, time to next treatment) rather than binary response metrics.

• In vitro resistance modeling:

  • Generate drug-resistant cell lines through long-term exposure to increasing drug concentrations.

  • Compare NFKBIE expression, mutation status, and pathway activity between parental and resistant lines.

  • Perform CRISPR-Cas9 knockout or overexpression of NFKBIE to directly assess its impact on drug sensitivity.

  • Use small molecule inhibitors of the NF-κB pathway in combination with standard therapies to test the reversibility of resistance.

• Comprehensive drug sensitivity testing:

  • Implement high-throughput drug screening to identify selective vulnerabilities in NFKBIE-altered cells.

  • Use databases like GSCALite to analyze correlations between NFKBIE expression and drug sensitivity profiles across cell line panels .

  • Test combinations of targeted agents to identify synergistic interactions that overcome resistance.

  • Include physiologically relevant microenvironmental factors (e.g., stromal co-culture) that may influence resistance mechanisms.

• Mechanistic studies:

  • Perform RNA-seq and phosphoproteomics before and after drug treatment to identify differentially activated pathways.

  • Use chromatin immunoprecipitation sequencing (ChIP-seq) to map changes in NF-κB binding patterns in resistant cells.

  • Implement ATAC-seq to identify alterations in chromatin accessibility that may contribute to transcriptional rewiring.

  • Apply single-cell approaches to characterize heterogeneity in drug response and identify pre-existing resistant subpopulations.

• In vivo validation:

  • Develop patient-derived xenograft models from treatment-naive and resistant tumors.

  • Use syngeneic mouse models with NFKBIE-modified tumors to assess impact on immunotherapy resistance.

  • Implement longitudinal sampling and sequencing to track clonal evolution during treatment.

These methodological approaches provide a comprehensive framework for understanding how NFKBIE alterations contribute to drug resistance, potentially identifying strategies to overcome resistance mechanisms in clinical settings .